Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | PDE4D | Q08499 | 7/20 | 0.39 |
| ▸ | PDE4A | P27815 | 3/20 | 0.39 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.39 |
| ▸ | PDE4C | Q08493 | 3/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5718421 | 0.90 | MAPT (0.42) | KDM4ELMNAKMT2AALDH1A1PDE4D | |
| SCHEMBL17320350 | 0.86 | KDM4E (0.39) | KDM4ELMNAKMT2AALDH1A1PDE4D | |
| SCHEMBL15906591 | 0.85 | KDM4E (0.38) | KDM4ELMNAKMT2AALDH1A1PDE4A | |
| SCHEMBL15899269 | 0.79 | KDM4E (0.36) | KDM4ELMNAKMT2AALDH1A1PDE4D | |
| SCHEMBL13988029 | 0.79 | KDM4E (0.45) | KDM4ELMNAKMT2AALDH1A1GAA | |
| SCHEMBL13989627 | 0.77 | PDE4D (0.43) | KDM4EKMT2AALDH1A1PDE4DPDE4A | |
| SCHEMBL13987170 | 0.77 | KDM4E (0.43) | KDM4ELMNAKMT2AALDH1A1GAA | |
| SCHEMBL13987169 | 0.77 | KDM4E (0.43) | KDM4ELMNAKMT2AALDH1A1GAA | |
| SCHEMBL9358766 | 0.76 | KDM4E (0.43) | KDM4ELMNAKMT2AALDH1A1GAA | |
| SCHEMBL14026620 | 0.75 | PDE4D (0.39) | KMT2AALDH1A1PDE4DPDE4APDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1966136-B1 | NOVEL PROCESS FOR PRODUCTION OF HIGHLY PURE POLYMORPH (I) DONEPEZIL HYDROCHLORIDE | RICHTER GEDEON NYRT (HU) | 2014-02-26 | — | — | EP | disclosed |
| EP-1954676-B1 | PROCESS FOR MAKING DONEPEZIL | SYNTHON BV (NL) | 2012-11-07 | — | — | EP | disclosed |
| US-20080306271-A1 | Novel Process for Production of Highly Pure Polymorph (I) Donepezil Hydrochloride | RICHTER GEDEON NYRT. (HU) | 2008-12-11 | — | — | US | disclosed |
| EP-1966136-A2 | NOVEL PROCESS FOR PRODUCTION OF HIGHLY PURE POLYMORPH (I) DONEPEZIL HYDROCHLORIDE | Richter Gedeon NYRT (HU) | 2008-09-10 | — | — | EP | disclosed |
| EP-1954676-A2 | PROCESS FOR MAKING DONEPEZIL | Synthon B.V. (NL) | 2008-08-13 | — | — | EP | disclosed |
| WO-2007072087-A2 | NOVEL PROCESS FOR PRODUCTION OF HIGHLY PURE POLYMORPH (I) DONEPEZIL HYDROCHLORIDE | RICHTER GEDEON NYRT. (HU) | 2007-06-28 | — | — | WO | disclosed |
| US-20070135644-A1 | PROCESS FOR MAKING DONEPEZIL | SYNTHON BV (NL) | 2007-06-14 | — | — | US | disclosed |
| WO-2007057226-A2 | PROCESS FOR MAKING DONEPEZIL | SYNTHON B.V. (NL) | 2007-05-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080306271-A1 | Novel Process for Production of Highly Pure Polymorph (I) Donepezil Hydrochloride | DRD4, IDO1, ADH1A | KDM4E 99/4885LMNA 2962/4885KMT2A 412/4885 |
| US-20070135644-A1 | PROCESS FOR MAKING DONEPEZIL | MAOA, ACHE, CHAT | KDM4E 104/4885LMNA 2498/4885KMT2A 24/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.